Form 4: Centessa Pharmaceuticals Acquisition Complete

Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company through a scheme of arrangement, with shareholders receiving cash and contingent value rights.

Summary

• Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company via a scheme of arrangement, effective June 24, 2026.
• Raphael Deferiere, Chief Accounting Officer, reported changes in beneficial ownership related to this transaction.
• Shareholders are entitled to receive $38.00 in cash per ordinary share, plus a contingent value right (CVR) for potential additional payments up to $9.00 per share.
• Restricted Share Units (RSUs) and share options were cancelled and converted into the right to receive the cash consideration and CVRs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for Centessa shareholders, as the acquisition provides a substantial cash payout and the potential for additional value through contingent rights, reflecting a successful exit.

Positives

• Shareholders will receive a significant cash payout of $38.00 per share.
• The inclusion of a contingent value right (CVR) offers the potential for additional future payments based on specified milestones.
• The acquisition by a major pharmaceutical company like Eli Lilly and Company suggests a positive valuation of Centessa's assets or pipeline.

Negatives

• The acquisition means Centessa Pharmaceuticals plc will cease to be a publicly traded entity, ending its independent operations.
• The contingent value of up to $9.00 per share is not guaranteed and depends on the achievement of future milestones.
• Existing share options and RSUs are cancelled and converted, rather than being exercised or settled in shares.

Risks

• The realization of the contingent value rights (CVRs) is subject to the achievement of specified milestones, which may not be met.
• Potential for disputes or disagreements regarding the achievement of milestones for CVR payouts.
• The transaction is subject to withholding taxes, reducing the net proceeds for shareholders.

Future Outlook

The future outlook for Centessa Pharmaceuticals plc as an independent entity is concluded due to the acquisition. Future value for former shareholders is tied to the contingent value rights (CVRs) which depend on the achievement of specified milestones.

Management Comments

• The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person.
• At the Effective Time, holders of Ordinary Shares became entitled to receive $38.00 in cash per Ordinary Share, plus one non-transferable contingent value right (CVR) entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share.

Industry Context

StockSavvy.ai notes that this acquisition by Eli Lilly and Company is consistent with the trend of large pharmaceutical companies acquiring smaller biotech firms to bolster their pipelines, particularly in areas with high unmet medical needs or promising early-stage assets.

Stakeholder Impact

• Shareholders: Receive $38.00 cash per share plus a CVR, representing a significant return on investment, but lose future upside potential of Centessa as an independent entity.
• Employees: May experience changes in roles, responsibilities, and employment terms under Eli Lilly and Company's ownership.
• Creditors: The acquisition terms do not appear to negatively impact existing creditors, as the transaction involves cash consideration for shareholders.

Next Steps

• Shareholders will receive the $38.00 cash consideration and contingent value rights.
• The achievement of specified milestones will determine any additional payments from the CVRs.

Key Dates

Recommendation

For existing Centessa shareholders, the recommendation is to 'hold' in the sense of accepting the offer, as it represents a favorable exit. For potential investors looking at Eli Lilly, this acquisition is a strategic move that could drive future growth, but the immediate impact on Eli Lilly's stock price is likely to be neutral to slightly positive, warranting a 'hold' or 'buy' depending on broader market conditions and Eli Lilly's valuation.

Keywords

Centessa Pharmaceuticals, Eli Lilly and Company, Acquisition, Scheme of Arrangement, Form 4, SEC Filing, Raphael Deferiere, Contingent Value Rights, Shareholder Value, Merger